Company
Oasmia Pharmaceutical AB
Headquarters: Uppsala, Sweden
Employees: 22
Market Cap
kr743.2 Million
SEK as of June 1, 2022
US$76.7 Million
Oasmia Pharmaceutical AB Categories
Sweden Healthcare Drug Manufacturers—Specialty & GenericSweden Healthcare Sweden Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. The company offers Apealea (paclitaxel micellar) for the treatment of ovarian cancer. Its products portfolio includes Docetaxel micellar, a patented formulation that combines XR-17 with docetaxel, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil, which has completed Phase I clinical trial for the treatment of ovarian cancer. The company's animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Oasmia Pharmaceutical AB (publ) was incorporated in 1988 and is headquartered in Solna, Sweden.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Oasmia Pharmaceutical AB has the following listings and related stock indices.
Stock: OMX: OASM wb_incandescent
Stock: OTC: OASMY wb_incandescent